Clinical trials: Visual Fields
Primary Open-angle Glaucoma (POAG) Patient
Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients
The purpose of this study is to investigate how the intraocular pressure (IOP) varies in time and if the IOP variations are associated with the worsening of glaucoma.
- Trial name
- NCT01828255
- Testing
- SENSIMED Triggerfish®
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sensimed AG
Chronic Low Back Pain
The Effects of the MME Procedure on Chronic Low Back Pain
The purpose of this study is to test whether or not the Magnetic Molecular Energizer (MME) device provides a well tolerated and effective intervention to reduce pain, pain-related symptoms and improve ability to function in those…
- Trial name
- NCT00325377
- Testing
- MME Procedure
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- Advanced Magnetic Research Institute International
Visual Field
To Compare the Octopus 311 and the Humphrey Field Analyzer 700 Series
To compare the Octopus 311 and the HFA 700 series
- Trial name
- NCT00441194
- Testing
- Visual Field (Octopus 311 and the HFA 700 series)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Haag Streit USA
Retinitis Pigmentosa, Stargardt Macular Dystrophy
Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.
- Conditions
- Retinitis Pigmentosa, Stargardt Macular Dystrophy, Stargardt Disease, Geographic Atrophy From Age-related Macular Degeneration
- Trial name
- DEFINE-IRD (NCT07502664)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Ray Therapeutics, Inc.
Relapsing Remitting Multiple Sclerosis, Optic Neuropathy
Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis
The objective of this trial is to assess the efficacy and safety of CNM-Au8 as a remyelinating treatment for vision-impairing MS lesions in participants who have chronic vision impairment as a result of Relapsing-Remitting…
- Conditions
- Relapsing Remitting Multiple Sclerosis, Optic Neuropathy, Optic; Neuritis, With Demyelination
- Trial name
- VISIONARY-MS (NCT03536559)
- Testing
- CNM-Au8
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 73 people
- Sponsor
- Clene Nanomedicine
Age Related Macular Degeneration
Correlation Between Visual Field Defects on Foresee Preferential Hyperacuity Perimeter(PHP) and on Optical Coherence Tomography (OCT) in Patients With Choroidal Neovascularization (CNV)
Study come to investigate the correlation between visual fields (VF) defects map generated by preferential hyperacuity perimeter (PHP) and features of the choroidal neovascular lesions (CNV) demonstrated by Optical Coherence…
- Trial name
- PHP (NCT00692887)
- Testing
- PHP - Preferential Hyperacuity Perimeter (Foresee)
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Notal Vision Ltd.
Ocular Hypertension, Open Angle Glaucoma
Study of AR-13324 in Patients With Elevated Intraocular Pressure
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days.
- Trial name
- NCT01528787
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 11 sites in United States
- Volunteers
- 85 people
- Sponsor
- Aerie Pharmaceuticals
Cognitive Change
PatiEnt Neuropsychological outcomeS After laseR Ablation
PatiEnt Neuropsychological outcomeS After laseR ablation
- Trial name
- PENSAR (NCT05075850)
- Testing
- Neuroblate System
- Where
- 7 sites in United States
- Volunteers
- 81 people
- Sponsor
- Monteris Medical
Glaucoma, Open-Angle
Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
To evaluate the efficacy of citicoline eye drops 2% in reducing visual field deterioration in patients with progressing OAG treated according to best clinical practice.
- Trial name
- NCT05710198
- Testing
- Citicoline eye drops 2%
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Omikron Italia S.r.l.
Visual Fields Hemianopsia, Hemianopsia, Homonymous
Visual Perceptual Learning for the Treatment of Visual Field Defect
This study evaluates the efficacy of visual perceptual learning for the treatment of visual field defect caused by brain damage.
- Trial name
- VIVID2 (NCT04102605)
- Testing
- Nunap Vision, Nunap Vision-C
- Where
- 5 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Nunaps Inc
Age Related Macular Degeneration
Correlation Between Visual Field Defects on FORESEE HOME and on Optical Coherence Tomography in Choroidal Neovascularization Subjects
The FORESEE HOME is used in the recent years to detect Age-related Macular Degeneration (AMD) lesions. The device is capable of differentiation as to stages of AMD and early detection of changes including choroidal…
- Trial name
- NCT00884637
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Notal Vision Ltd.
Visual Fields Hemianopsia, Hemianopsia, Homonymous
Visual Perceptual Learning Based Digital Therapeutics for Visual Field Defect After Stroke
This study evaluates the efficacy of visual perceptual learning for the treatment of visual field defect caused by brain disease. Half of participants will receive visual perceptual training using the VIVID Brain.
- Trial name
- NCT05525949
- Testing
- VIVID Brain, No-treatment Control
- Where
- 12 sites in South Korea
- Volunteers
- 93 people
- Sponsor
- Nunaps Inc
Symptomatic Vitreomacular Adhesion
A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
The purpose of this study is to evaluate the superiority regarding vitreomacular adhesion (VMA) resolution of a single intravitreal injection of A01016 (Ocriplasmin) compared to sham-injection in subjects with symptomatic VMA.
- Trial name
- NCT01889251
- Testing
- Ocriplasmin
- Where
- Japan
- Volunteers
- 251 people
- Sponsor
- Alcon Research
Laparoscopic Cholecystectomy
Feasibility of the Ultravision™ System in Low Pressure Laparoscopic Cholecystectomy Compared to Airseal® IFS
This post-market clinical study is designed to evaluate the effectiveness of the Ultravision™ System when compared to the Airseal® iFS within an approved indication for use, namely laparoscopic cholosystectomy.
- Trial name
- NCT04162106
- Testing
- Smoke management during laparoscopic cholecystectomy using the Ultravision™ System, Smoke management during laparoscopic cholecystectomy using the Airseal® iFS
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Alesi Surgical Ltd.
Neuro-Ophthalmology
Safety and Normative Data With Neos™
The goal of this clinical study is to collect standard data for the medical device neos™. neos™ is a system that shows images and measures the resulting eye movements and pupil size. Collecting standard data involves three steps.
- Trial name
- neos-SNOW (NCT07258212)
- Where
- 3 sites in Switzerland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- machineMD AG
Low Tension Glaucoma
Observational Study of the Long-term Effect of Latanoprost in Normal Tension Glaucoma
The purpose of this study is to assess the long-term efficacy and safety of latanoprost monotherapy in patients with normal tension glaucoma (NTG) using a prospective, observational design.
- Trial name
- NTG-X-PERT (NCT01209624)
- Volunteers
- 902 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Homonymous Hemianopsia, Homonymous Quadrantanopia
PAVE (Parallactic Visual-Field Enhancement) System for Treatment of Chronic Visual Field Loss Due to Stroke, Traumatic Brain Injury, or Brain Surgery
This is a research study to evaluate the effectiveness of the PAVE (Parallactic Visual-Field Enhancement) System for the treatment of chronic visual field loss due to stroke, traumatic brain injury, or brain surgery.
- Trial name
- NCT07185971
- Testing
- PAVE (Parallactic Visual-Field Enhancement) treatment using a virtual reality head mounted display
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- NeuroAEye LLC
Age Related Macular Degeneration, Cognition Disorders
The Zeaxanthin and Visual Function Study
To evaluate if supplementation of zeaxanthin (with or without Lutein) is beneficial to patients with early and moderate Atrophic Age Related Macular Degeneration.
- Trial name
- ZVF (NCT00564902)
- Testing
- 3R 3'R Zeaxanthin, Lutein, Lutein and Zeaxanthin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Chrysantis, Inc.
Glaucoma
Clinical Evaluation of Visual Field Change in Glaucoma: an Assessment of Different Models of Progression
The purpose of this observational study is to collect over time a series of data in patients with glaucoma in order to evaluate different approaches in defining the progression of this pathology.
- Trial name
- NCT05801471
- Where
- 2 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Centervue SpA
Age Related Macular Degeneration, Choroidal Neovascularization
Comparison Between Home Macular Perimeter and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)
The FORESEE HOME is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with Age Related Macular Degeneration (AMD).
- Trial name
- NCT01336907
- Where
- France
- Sponsor
- Notal Vision Ltd.